ID: ALA277646

Max Phase: Preclinical

Molecular Formula: C26H17Cl2N3O

Molecular Weight: 458.35

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cn1cncc1C(O)(C#Cc1ccc(Cl)cc1-c1cccc(Cl)c1)c1ccc(C#N)cc1

Standard InChI:  InChI=1S/C26H17Cl2N3O/c1-31-17-30-16-25(31)26(32,21-8-5-18(15-29)6-9-21)12-11-19-7-10-23(28)14-24(19)20-3-2-4-22(27)13-20/h2-10,13-14,16-17,32H,1H3

Standard InChI Key:  AYVGITDSDRJQKI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 458.35

Molecular Weight (Monoisotopic): 457.0749

AlogP: 5.55

#Rotatable Bonds: 3

Polar Surface Area: 61.84

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.20

CX Basic pKa: 5.87

CX LogP: 5.71

CX LogD: 5.70

Aromatic Rings: 4

Heavy Atoms: 32

QED Weighted: 0.41

Np Likeness Score: -1.02

References

1. Lin NH, Wang L, Cohen J, Gu WZ, Frost D, Zhang H, Rosenberg S, Sham H..  (2003)  Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor.,  13  (7): [PMID:12657267] [10.1016/s0960-894x(03)00122-7]

Source

Source(1):

• Scientific Literature